Product Details

The anterior pituitary can be accomplished, in general, by combining a growth hormone releasing hormone (GHRH) analogue with a growth hormone secretagogue receptor (GHSR) agonist. There are multiple combinations that can accomplish this goal,including combining modified GRF with ipamorelin. Of course. somet imes the goal might be to achieve more specific effects in addition to maximum GH release. In other words, by fine tuning the types of GHRH agonist and GHSR agonist used, it could be possible to create more targeted outcomes.In the case of Modified GRF, a potent GHRH analogue,the effects go beyond simply boosting GH release. The peptide has been shown,in animal studies,to have benefits in intestinal inflammation, heart function, and wound healing. By adding ipamorelin to the mix with modified GRF, GH release is pulsed to its maximum level. lpamorelin, known for its specificity in boosting GH with few additional effects, has recently been linked to bone regrowth and matrix stabilization.These effects appear to be in addition to the bone benefits of enhanced GH release.

Finally,it is possible to boost targeted fat burning, something that both modified GRF and ipamorelin cause to a limited degree,with the aid of fragment 176-191. While technically a GHRH agonist, fragment 176-191has been shown in animal models to be a primary and potent stimulator of adipocyte catabolism (fat burning). The peptide is orders of magnitude more potent than most GHRH agonists in stimulating fat metabolism and thus is sometimes referred to as the “lipolytic fragment.” Adding fragment 176-191to the mix is a way to boost fat burning, particularly in the setting of enhanced GH release , and shift metabolism toward the accumulation of lean body mass.